Allogeneic stem cell transplantation achieves long-term remissions in mantle cell lymphoma, including in TP53 -mutated disease.

Autor:	Lew TE; Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia.; Blood Cells and Blood Cancer Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia.; Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Australia., Cliff ERS; Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia.; Program on Regulation, Therapeutics and Law, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Dickinson M; Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia., Tam CS; Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia.; Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Australia.; Alfred Hospital and Monash University, Melbourne, Australia., Seymour JF; Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia.; Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Australia., Blombery P; Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia.; Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Australia.; Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, Australia., Bajel A; Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia., Ritchie D; Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia.; Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia., Khot A; Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia.; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.
Jazyk:	angličtina
Zdroj:	Leukemia & lymphoma [Leuk Lymphoma] 2023 Nov-Dec; Vol. 64 (11), pp. 1792-1800. Date of Electronic Publication: 2023 Aug 02.
DOI:	10.1080/10428194.2023.2241095
Abstrakt:	Cytarabine-containing chemoimmunotherapy followed by autologous transplantation and rituximab maintenance achieves durable remissions for most patients with mantle cell lymphoma (MCL). However, patients with TP53 -mutated disease have poor outcomes with standard approaches. We previously reported that allogeneic stem cell transplantation (alloSCT) achieved durable remissions in MCL, however follow-up among patients with TP53 -mutated disease was limited. Here we report extended follow-up of the overall cohort ( n =  36) and TP53- mutated subset (n =  13) (median follow-up 10.8 and 4.2 years, respectively). Estimated overall survival was 56% at 10 years for the overall cohort and 59% at 4 years for the TP53- mutated subset. Among patients with TP53- mutated disease, no relapses occurred beyond 6 months post-transplant. Survival after post-alloSCT disease relapse was poor (median 2.1 years). These data confirm that alloSCT can be curative in MCL, including patients with TP53 -mutated disease, and should be considered for earlier utilization in this subgroup for whom conventional chemoimmunotherapy is ineffective.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu